We are live on ! Find out more
OCUL icon

Ocular Therapeutix
OCUL

149 hedge funds and large institutions have $1.04B invested in Ocular Therapeutix in 2020 Q4 according to their latest regulatory filings, with 54 funds opening new positions, 48 increasing their positions, 35 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

315% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 13

246% more capital invested

Capital invested by funds: $301M → $1.04B (+$742M)

147% more call options, than puts

Call options by funds: $12.3M | Put options by funds: $4.96M

100% more funds holding in top 10

Funds holding in top 10: 5 → 10 (+5)

38% more funds holding

Funds holding: 108 → 149 (+41)

37% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 35

3.8% more ownership

Funds ownership: 63.18% → 66.98% (+3.8%)

Holders
149
Holders Change
+41
Holders Change %
+37.96%
% of All Funds
2.64%
Holding in Top 10
10
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+100%
% of All Funds
0.18%
New
54
Increased
48
Reduced
35
Closed
13
Calls
$12.3M
Puts
$4.96M
Net Calls
+$7.31M
Net Calls Change
+$7.48M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$21.2M
2
EA
Emerald Advisers
Pennsylvania
+$17.7M
3
EMFAT
Emerald Mutual Fund Advisers Trust
Pennsylvania
+$16.7M
4
Victory Capital Management
Victory Capital Management
Texas
+$16.1M
5
GPP
Great Point Partners
Connecticut
+$12.7M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$29.4M
2
IC
Ikarian Capital
Texas
-$15.3M
3
VVM
Versant Venture Management
California
-$11.1M
4
ECM
Endurant Capital Management
California
-$8.12M
5
DAM
Deltec Asset Management
New York
-$4.51M
Name Holding Trade Value Shares
Change 		Change in
Stake
LCG
26
Lisanti Capital Growth
New York
$7.58M +$5.44M +366,040 New
Renaissance Technologies
27
Renaissance Technologies
New York
$6.92M +$4.96M +334,066 New
CM
28
Castleark Management
Illinois
$6.76M +$4.85M +326,642 New
Bank of New York Mellon
29
Bank of New York Mellon
New York
$6.69M +$2.02M +135,811 +72%
ACM
30
Altium Capital Management
New York
$6.28M +$4.5M +303,174 New
Wells Fargo
31
Wells Fargo
California
$6.26M +$2.02M +135,832 +81%
EI
32
EAM Investors
California
$6.06M +$539K +36,325 +14%
ECM
33
Endurant Capital Management
California
$6.01M -$8.12M -546,672 -65%
Morgan Stanley
34
Morgan Stanley
New York
$5.42M -$40.2K -2,710 -1%
APM
35
Avidity Partners Management
Texas
$5.17M +$3.71M +250,000 New
Federated Hermes
36
Federated Hermes
Pennsylvania
$5.15M +$3.69M +248,702 +118,996%
AAA
37
Affinity Asset Advisors
New York
$4.55M +$3.27M +220,000 New
NA
38
Nottingham Advisors
New York
$4.05M – – –
Fidelity Investments
39
Fidelity Investments
Massachusetts
$3.83M +$2.1M +141,221 +324%
Susquehanna International Group
40
Susquehanna International Group
Pennsylvania
$3.73M +$626K +42,120 +31%
Charles Schwab
41
Charles Schwab
California
$3.49M +$314K +21,150 +14%
EGI
42
EAM Global Investors
California
$3.39M -$615K -41,383 -20%
California Public Employees Retirement System
43
California Public Employees Retirement System
California
$2.84M +$7.32K +493 +0.4%
Swiss National Bank
44
Swiss National Bank
Switzerland
$2.84M +$2.04M +137,100 New
California State Teachers Retirement System (CalSTRS)
45
California State Teachers Retirement System (CalSTRS)
California
$2.15M +$181K +12,202 +13%
State of Wisconsin Investment Board
46
State of Wisconsin Investment Board
Wisconsin
$2.08M -$96.5K -6,500 -6%
PPA
47
Parametric Portfolio Associates
Washington
$2.03M +$1.26M +84,789 +637%
QP
48
Quilter Plc
United Kingdom
$2.02M -$2.97K -200 -0.2%
Assenagon Asset Management
49
Assenagon Asset Management
Luxembourg
$1.99M +$1.42M +95,895 New
Royal Bank of Canada
50
Royal Bank of Canada
Ontario, Canada
$1.77M -$104K -7,012 -8%
1
2
3 4 5

OCUL Hedge Fund Activity: Q4 2020 in Review

149 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q4 2020, worth a combined $1.04B — up 246% from $301M a quarter earlier.

Buyers outnumbered sellers: 54 funds opened new OCUL positions and 13 closed out — a net gain of 41 holders — while 48 added to existing stakes and 35 trimmed.

The largest buyer was BlackRock, adding an estimated $21.2M. The largest seller was RA Capital Management, cutting an estimated $29.4M.

  • 149 institutional investors held Ocular Therapeutix (OCUL) as of Q4 2020, up from 108 in Q3 2020.
  • Funds reported $1.04B of Ocular Therapeutix stock for Q4 2020, up 246% quarter-over-quarter.
  • 54 funds opened new Ocular Therapeutix positions in Q4 2020 and 13 closed out, a net change of +41 holders.
  • The largest Ocular Therapeutix buyer in Q4 2020 was BlackRock, an estimated $21.2M added.
  • The largest Ocular Therapeutix seller in Q4 2020 was RA Capital Management, an estimated $29.4M sold.

Based on aggregated 13F filings for Q4 2020.